医学
乳腺癌
美容
新辅助治疗
化疗
放射治疗
肿瘤科
阶段(地层学)
癌症
内科学
激素疗法
外科
古生物学
生物
作者
Adam Ofri,K Elstner,G. Bruce Mann,Shicha Kumar,Sunil Warrier
标识
DOI:10.1016/j.surge.2023.04.001
摘要
Breast cancer is the most common non-skin cancer in Australia, affecting 1 in 7 women by the age of 85 years. Current management of early breast cancer is becoming increasingly variable and complex. The typical range of treatments include some combination of surgery, chemotherapy and targeted therapy, immunotherapy, radiotherapy, and endocrine therapy. Neoadjuvant chemotherapy (NACT) in carefully selected patients can facilitate increased rates of breast conservation therapy, and when successful, offers improved cosmesis due to less extensive resection of tissue. A neoadjuvant approach also provides biological insight into a patient's tumour, prognostication based on a patient's response to therapy, as well as enabling their treating oncologist to personalise adjuvant strategies based on the presence or absence of residual cancer at surgery. Neoadjuvant chemotherapy has become an integral element in the provision of breast conserving surgery to selected early-stage breast cancer patients. Appreciating the indications and understanding the likely outcomes from NACT in select situations, can result in significant improvements in patient tailored care.
科研通智能强力驱动
Strongly Powered by AbleSci AI